CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+9.19%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(-9.9%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
93
Reduced
281
Closed
40
Top Buys
| 1 |
NVIDIA
NVDA
|
$40.6M |
| 2 |
Apple
AAPL
|
$9.08M |
| 3 |
Applied Materials
AMAT
|
$5.39M |
| 4 |
Arista Networks
ANET
|
$5.26M |
| 5 |
Amphenol
APH
|
$5.14M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.02M |
| 2 |
Adobe
ADBE
|
$7.95M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$7.6M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$6.84M |
| 5 |
Lam Research
LRCX
|
$5.23M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
226
Verona Pharma
VRNA
$9.18B
| $222K | 0.03% |
15,350
-4,850
| -24% | -$70.1K |
|
|
MORF
227
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $222K | 0.03% |
6,512
-3,118
| -32% | -$106K |
|
228
NovoCure
NVCR
$1.33B
| $217K | 0.03% |
12,642
-7,938
| -39% | -$136K |
|
229
Fastenal
FAST
$56.8B
| $216K | 0.03% |
3,442
+861
| +33% | +$54.1K |
|
230
Kymera Therapeutics
KYMR
$3.03B
| $215K | 0.03% |
7,208
-4,545
| -39% | -$136K |
|
231
Diamondback Energy
FANG
$41.2B
| $215K | 0.03% |
1,072
+267
| +33% | +$53.5K |
|
232
Arvinas
ARVN
$577M
| $214K | 0.03% |
8,040
-5,024
| -38% | -$134K |
|
233
Autoliv
ALV
$9.52B
| $214K | 0.03% |
2,000
-1,000
| -33% | -$107K |
|
234
GE HealthCare
GEHC
$32.9B
| $214K | 0.03% |
2,744
+690
| +34% | +$53.8K |
|
235
Baker Hughes
BKR
$44.2B
| $211K | 0.03% |
6,000
+1,485
| +33% | +$52.2K |
|
236
Novavax
NVAX
$1.22B
| $209K | 0.03% |
16,495
-10,383
| -39% | -$131K |
|
237
Exelon
EXC
$43.5B
| $208K | 0.03% |
6,013
+1,505
| +33% | +$52.1K |
|
238
Apogee Therapeutics
APGE
$2.27B
| $208K | 0.03% |
5,284
-1,871
| -26% | -$73.6K |
|
239
Syndax Pharmaceuticals
SNDX
$1.37B
| $205K | 0.03% |
9,984
-6,354
| -39% | -$130K |
|
240
Ardelyx
ARDX
$1.56B
| $204K | 0.03% |
27,488
-17,266
| -39% | -$128K |
|
241
Cognizant
CTSH
$34.9B
| $203K | 0.03% |
2,989
+743
| +33% | +$50.5K |
|
242
iShares US Technology ETF
IYW
$22.8B
| $203K | 0.03% |
+1,350
| New | +$203K |
|
243
Recursion Pharmaceuticals
RXRX
$2.01B
| $203K | 0.03% |
27,054
-16,602
| -38% | -$125K |
|
244
Harmony Biosciences
HRMY
$2.13B
| $201K | 0.03% |
6,672
-4,221
| -39% | -$127K |
|
245
Coca-Cola Europacific Partners
CCEP
$39.3B
| $201K | 0.03% |
2,761
+701
| +34% | +$51.1K |
|
246
Edgewise Therapeutics
EWTX
$1.54B
| $198K | 0.03% |
10,973
-6,908
| -39% | -$124K |
|
247
Veracyte
VCYT
$2.38B
| $195K | 0.03% |
8,983
-5,464
| -38% | -$118K |
|
248
Keros Therapeutics
KROS
$641M
| $194K | 0.03% |
4,239
-2,677
| -39% | -$122K |
|
249
Akero Therapeutics
AKRO
$3.62B
| $191K | 0.03% |
8,124
-2,676
| -25% | -$62.8K |
|
250
Mirum Pharmaceuticals
MIRM
$3.72B
| $189K | 0.03% |
5,537
-3,415
| -38% | -$117K |
|